Formulation: A solution in methyl acetate
Formal Name: 4-[[2R-[3R-hydroxy-2-[3S-hydroxy-4-[3-(methoxymethyl)phenyl]-1R-buten-1E-yl]-5-oxocyclopentyl]ethyl]thio]-butanoic acid, methyl ester
Purity: ≥98%
Formula Markup: C24H34O6S
Formula Weight: 450,6
Shelf life (days): 365
CAS Number: 256382-08-8
Notes: Rivenprost is a prodrug of the active free acid form, an agonist of the PGE2 receptor subtype EP4.{19381,61793} Rivenprost (tested as the free acid) is selective for the EP4 receptor over the EP3, EP2, and EP1 receptor subtypes (Kis = 0.7, 56, 620, and >10,000 nM, respectively). It enhances bone morphogenic protein-induced increases in alkaline phosphatase activity, a marker of osteoblastic differentiation, in primary mouse calvarial osteoblasts when used at a concentration of 100 nM.{18824} Rivenprost decreases LPS-induced increases in plasma TNF-α levels in rats in a dose-dependent manner.{19381} It decreases trabecular separation, as well as increases bone volume, in rats when administered at a dose of 10 µg/kg.{18825} Rivenprost (3 and 10 mg/kg) increases proximal tibiae biomechanical strength in ovariectomized rats.{18823}
English
Deutsch
